LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LSBCF advanced for three days, in of 133 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 04, 2025. You may want to consider a long position or call options on LSBCF as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for LSBCF just turned positive on November 04, 2025. Looking at past instances where LSBCF's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
LSBCF moved above its 50-day moving average on November 04, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LSBCF crossed bullishly above the 50-day moving average on November 11, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
LSBCF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LSBCF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.487) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (0.184) is also within normal values, averaging (322.723).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LSBCF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LSBCF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
A.I.dvisor indicates that over the last year, LSBCF has been loosely correlated with STTK. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if LSBCF jumps, then STTK could also see price increases.
| Ticker / NAME | Correlation To LSBCF | 1D Price Change % | ||
|---|---|---|---|---|
| LSBCF | 100% | +2.36% | ||
| STTK - LSBCF | 38% Loosely correlated | -3.03% | ||
| BCTX - LSBCF | 30% Poorly correlated | -4.08% | ||
| GLTO - LSBCF | 27% Poorly correlated | +0.08% | ||
| PROK - LSBCF | 26% Poorly correlated | -4.29% | ||
| GNFT - LSBCF | 23% Poorly correlated | +6.77% | ||
More | ||||